DalCor Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11004
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DalCor Pharmaceuticals Inc (DalCor Pharmaceuticals) researches and develops precision medicine for patients suffering from cardiovascular diseases. The company is engaged in development of Dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor which is intended to reduce cardiovascular events in a genetically distinct subset of patients. DalCor Pharmaceuticals is also engaged in the development of dal- GenE which is used for the treatment of cardiovascular death, myocardial infarction (heart attack) and stroke. The company operates in Canada, the US, Switzerland and the UK. DalCor Pharmaceuticals is headquartered in Montreal, Quebec, Canada.

DalCor Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
DalCor Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
DalCor Pharma Raises USD78 Million in Series B Financing 11
DalCor Pharma Raises USD36.1 Million in Series A Financing 12
Private Equity 13
Fonds de solidarite FTQ Invests USD7.5 Million in DalCor Pharma 13
Licensing Agreements 14
Roche Enters into Licensing Agreement with Dalcor Pharma 14
Dalcor Pharma Enters into Licensing Agreement with Montreal Heart Institute Research Centre 15
DalCor Pharmaceuticals Inc – Key Competitors 16
DalCor Pharmaceuticals Inc – Key Employees 17
DalCor Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Apr 09, 2018: DalCor Pharmaceuticals Names Dr. Fouzia Laghrissi-Thode As Chief Executive Officer 19
Nov 15, 2017: DalCor Pharmaceuticals Appoints Dr. Fouzia Laghrissi-Thode to the Board of Directors 20
Clinical Trials 21
Mar 07, 2017: DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule 21
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DalCor Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
DalCor Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DalCor Pharma Raises USD78 Million in Series B Financing 11
DalCor Pharma Raises USD36.1 Million in Series A Financing 12
Fonds de solidarite FTQ Invests USD7.5 Million in DalCor Pharma 13
Roche Enters into Licensing Agreement with Dalcor Pharma 14
Dalcor Pharma Enters into Licensing Agreement with Montreal Heart Institute Research Centre 15
DalCor Pharmaceuticals Inc, Key Competitors 16
DalCor Pharmaceuticals Inc, Key Employees 17
DalCor Pharmaceuticals Inc, Other Locations 18

List of Figures
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
DalCor Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[DalCor Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sky plc (SKY):企業の財務・戦略的SWOT分析
    Sky plc (SKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • The Tokyo Electric Power Company, Incorporated:企業の戦略・SWOT・財務情報
    The Tokyo Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Tokyo Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • St. George’s University of London:製薬・医療:M&Aディール及び事業提携情報
    Summary St. George's University of London (SGUL), a subsidiary of University of London is a medical and healthcare education provider. It offers undergraduate and post graduate courses. The university’s undergraduate courses include biomedical science BSc, healthcare practice DipHE and BSc, healthca …
  • Innogy SE (IGY):電力:M&Aディール及び事業提携情報
    Summary Innogy SE (Innogy), a subsidiary of RWE AG, is an energy company. The company offers electricity and natural gas. It operates through its business segments such as renewables, grid and infrastructure, and retail. Innogy’s company’s grid and infrastructure segment operates electricity and gas …
  • FMC Corp (FMC):企業の財務・戦略的SWOT分析
    FMC Corp (FMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Shougang Fushan Resources Group Limited.:企業の戦略・SWOT・財務情報
    Shougang Fushan Resources Group Limited. - Strategy, SWOT and Corporate Finance Report Summary Shougang Fushan Resources Group Limited. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Sangamo Therapeutics Inc (SGMO)-製薬・医療分野:企業M&A・提携分析
    Summary Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biopharmaceutical company which focuses on the research and development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation and therapeutic genome editing. The company is …
  • Virginia Electric and Power Co:企業の戦略的SWOT分析
    Virginia Electric and Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Merus NV (MRUS):企業の財務・戦略的SWOT分析
    Summary Merus NV (Merus) is a clinical-stage immuno-oncology company that discovers and develops human bispecific antibody therapeutics for the treatment of cancer. The company’s pipeline antibody candidates are intended for the treatment of breast cancer, ovarian cancer, colorectal cancer, acute my …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Singapore Power Limited:企業の戦略・SWOT・財務情報
    Singapore Power Limited - Strategy, SWOT and Corporate Finance Report Summary Singapore Power Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Imperial College London:企業のM&A・事業提携・投資動向
    Imperial College London - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Imperial College London Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Sky plc (SKY):企業の財務・戦略的SWOT分析
    Sky plc (SKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Penske Automotive Group, Inc.:企業のM&A・事業提携・投資動向
    Penske Automotive Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Penske Automotive Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Lotte Holdings Co. Ltd.:企業の戦略・SWOT・財務情報
    Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Stada Arzneimittel AG (SAZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of product …
  • GridEdge Networks Inc.:企業の戦略的SWOT分析
    GridEdge Networks Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Fractyl Laboratories Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fractyl Laboratories Inc (Fractyl) is a clinical-stage medical technology company that develops novel devices and procedures to overcome insulin resistance and restitute metabolic health. The company developed a device-based clinical platform to change the way of treating metabolic diseases. …
  • AbCheck sro:製薬・医療:M&Aディール及び事業提携情報
    Summary AbCheck Sro (AbCheck), a subsidiary of Affimed NV is a healthcare technology company offers discovery and optimization of high-quality human antibodies. The company offers technology platforms such as Absieve, and AbAccel. Its Absieve is an antibody discovery technology that offers proprieta …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆